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E-mail address: gabriele.pradel@uni-wuerzburg.deThe ubiquitin/proteasome system serves as a regulated protein degradation pathway in eukaryotes, and
is involved in many cellular processes featuring high protein turnover rates, such as cell cycle control,
stress response and signal transduction. In malaria parasites, protein quality control is potentially impor-
tant because of the high replication rate and the rapid transformations of the parasite during life cycle
progression. The proteasome is the core of the degradation pathway, and is a major proteolytic complex
responsible for the degradation and recycling of non-functional ubiquitinated proteins. Annotation of the
genome for Plasmodium falciparum, the causative agent of malaria tropica, revealed proteins with similar-
ity to human 26S proteasome subunits. In addition, a bacterial ClpQ/hslV threonine peptidase-like pro-
tein was identiﬁed. In recent years several independent studies indicated an essential function of the
parasite proteasome for the liver, blood and transmission stages. In this review, we compile evidence
for protein recycling in Plasmodium parasites and discuss the role of the 26S proteasome as a prospective
multi-stage target for antimalarial drug discovery programs.
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The proteasome is a major proteolytic complex responsible for
the degradation and recycling of proteins and therefore plays an
important role in intracellular protein quality control. The protea-
some mediates the degradation of many short-lived proteins that
are involved in cell cycle regulation, signal transduction and apop-
tosis, and is also responsible for the recycling of abnormal or dam-Published by Elsevier Ltd.
fax: +49 (0)931 31 82578.
(G. Pradel).
Open acaged proteins, which would otherwise accumulate and become
harmful to the cell (reviewed in Pickart and Cohen, 2004). The pro-
teasome is part of the ubiquitin-proteasome system (UPS), which
manages proteostasis in the cell. Via an UPS-speciﬁc enzymatic
cascade, proteins become labelled with a small ubiquitin (Ub)
tag. The type of ubiquitination then determines whether a protein
is designated for further roles in cellular processes like DNA repair,
trafﬁcking or signal transduction, or whether it will be degraded by
the proteasome (reviewed in Hendil and Hartmann-Petersen,
2004; Pickart and Cohen, 2004; Clague and Urbe, 2010). Because
eukaryotic proteostasis is central to cell development, deﬁcienciescess under CC BY-NC-ND license.
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vascular disorders (reviewed in Balch et al., 2008).
Protein regulation appears to be important for the rapid trans-
formations of the malaria parasite during life cycle progression in
target organs of the human host and the mosquito vector, including
stages having high replication rates. Shifts in temperature, to which
the parasite is exposed when rapidly adapting from human to mos-
quito, and vice versa, might additionally induce a stress response
requiringmanagement by the UPS. In silico predictions indicate that
over half of the parasite proteins represent targets for ubiquitina-
tion (Ponts et al., 2011). The human malaria parasite, Plasmodium
falciparum, appears to possess a functional eukaryotic proteasome
and a bacterial ClpQ/hslV threonine peptidase-like protein complex
(reviewed in Chung and Le Roch, 2010; Tschan et al., 2011), but
their speciﬁc roles within the parasite are not known.
The proteasome has long been explored as an anti-cancer drug
target (reviewed in Kisselev and Goldberg, 2001), based upon the
observation that proteasome inhibition can induce apoptosis pref-
erentially in cancer cells. In 2003 the proteasome inhibitor bort-
ezomib (Velcade, PS-341) was approved by the US Food and
Drug Administration for the treatment of multiple myeloma (Kane
et al., 2003). Since then, a stream of new proteasome inhibitors
have been pursued in clinical trials (reviewed in Orlowski and
Kuhn, 2008; de Bettignies and Coux, 2010).
In Plasmodium, inhibitor studies reveal an essential role of the
proteasome for the liver, blood and transmission stages (Gantt
et al., 1998; Lindenthal et al., 2005; Reynolds et al., 2007; Kreiden-
weiss et al., 2008; Prudhomme et al., 2008; Czesny et al., 2009;
Schoof et al., 2010; Aminake et al., 2011), thus suggesting the pro-
teasome as a promising multi-stage target in malaria therapy. The
World Health Organization (WHO) recommends artemisinin-based
combination therapies for the treatment of malaria, with compo-
nent drugs having independent targets in order to gain control of
drug-resistant parasites (WHO Guidelines for the Treatment of Ma-
laria 2010). Ideally, such antimalarials would further exhibit activ-
ities against the liver and transmission stages of the pathogen.
Inhibitors targeting the plasmodial proteasome might well fulﬁll
these requirements, and antimalarial drug development programs
might beneﬁt from developments in anti-cancer proteasome inhib-
itors having improved speciﬁcity, tolerance and bioavailability.
While the Plasmodium proteasome begins to draw attention as an
antimalarial drug target, our understanding of protein regulation in
malaria parasites remains rudimentary. It is inferred that the struc-
ture and functionof theplasmodialUPS is similar to other eukaryotes,
based on a generally high level of conservation. However, primary
data on these assumptions are fragmented, and it is not clear towhat
degree theUPS has adapted to the requirements of the highly special-
ized malaria parasite. To reveal detailed function of the parasite UPS,
it will be necessary to study UPS-mediated protein regulation and
proteasomal degradation of target proteins. This review highlights
current knowledge of the plasmodial proteasome; investigates the
range of UPS proteins in the parasite; and discusses the potential role
of the proteasome as a target for antimalarial drugs.2. The composition of the proteasome
The 26S proteasome is a 2.5 MDa complex involved in the reg-
ulated degradation of ubiquitinated proteins. It is composed of
more than 33 subunits (SUs), which form a proteolytic barrel-like
20S core particle (CP), capped by two 19S regulatory particles
(RPs) (Fig. 1). The RP is involved in ATP-dependent recognition,
binding and unfolding of ubiquitinated proteins, while the CP is
important for proteolysis (reviewed in Marques et al., 2009;
Bedford et al., 2010; Xie, 2010). The CP is formed by four staged
heptameric rings: two outer rings, consisting of seven a-SUs perring, and two inner rings composed of seven b-SUs each. Substrate
peptide bonds are hydrolyzed by N-terminal active site threonine
residues, which are embedded in the core of the CP’s b-SUs. Three
of the seven different b-SUs are proteolytically active; namely, b1,
b2 and b5, displaying caspase-, trypsin-, and chymotrypsin-like
activities, respectively (Arendt and Hochstrasser, 1997; Heinemey-
er et al., 1997). More recent data suggest that the performance of
the different active sites are interdependent and may have speciﬁc
functional relevance (Kisselev et al., 2006; Britton et al., 2009).
Because the proteolytic sites are sequestered in the closed bar-
rel, activators are required to facilitate access to the CP, thus ensur-
ing that protein degradation occurs only if the substrate is
unfolded (reviewed in Gallastegui and Groll, 2010). In addition to
the 19S RP, it was shown for the human and yeast proteasomes
that the CP is able to associate with one of two known ATP-inde-
pendent activators, the 11S/PA28 heteroheptamer complex and
the large heat-repeat containing protein PA200/Blm10 (reviewed
in Stadtmüller and Hill, 2011). While 11S/PA28 and PA200/Blm10
are reported to preferentially support hydrolysis of peptides, the
RP is involved in the degradation of proteins with higher complex-
ity (reviewed in O’Donoghue and Gordon, 2006).
The CP can associate with one or two of the 19S RPs. The RP rec-
ognizes the ubiquitinated protein, assists in deubiquitination and
unfolds the substrate, which is subsequently translocated into the
CP cavity. The RP is divided into two sub-complexes, the base and
the lid (Fig. 1; reviewed in Bedford et al., 2010;Gallastegui andGroll,
2010). The RP base comprises six different AAA-typeATPase SUs, the
regulatory particle triple A proteins (Rpt1-6), as well as four non-
ATPase SUs, the regulatory particle non-ATPase proteins Rpn1,
Rpn2, Rpn10 and Rpn13. Rpn10 and Rpn13 are ubiquitin receptors,
while Rpn1andRpn2 function as scaffold. Rpn10 acts as a linker pro-
tein between the base and the lid. The lid consists of nine Rpn-type
SUs; namely, Rpn3, Rpn5-9, Rpn11, Rpn12 and Rpn15.
In P. falciparum, 14 putative proteins homologous to the yeast
CP were identiﬁed (Mordmüller et al., 2006). CP-SUs a5 and b5
were recently shown to be present in the cytoplasm and nucleus
of blood stage parasites, particularly in trophozoites and schizonts
(Fig. 2A, B; Aminake et al., 2011; Aminake and Pradel, unpublished
observations). This is in accordance with recent ﬁndings reporting
a peak of ubiquitinated proteins in these stages (Ponts et al., 2011).
The proteasome is further expressed in gametocytes of both gen-
ders during their differentiation from stage I to stage V (Fig. 2A,
B; Aminake et al., 2011; Aminake and Pradel, unpublished observa-
tions), pointing to high protein turnover activities in these stages.
In order to identify parasite homologs to proteasomal SUs, we
performed a BLAST search using human proteasome SU proteins
(http://www.uniprot.org) as queries against the P. falciparum 3D7
genome (http://plasmodb.org; Aurrecoechea et al., 2009). Pre-
dicted homologs of proteasome precursor or SU sequences were
ranked as having high score segment pairs and low P-values. The
computational analysis revealed plasmodial homologs for all of
the human 26S proteasome SUs (Table 1). These in silico results
provide a ﬁrst indication for the presence of a 26S proteasome in
malaria parasites. Biochemical studies will be required to provide
direct evidence for the physical presence, interaction and proteo-
lytic activities of the predicted SUs.
We further identiﬁed a homolog to the human ATP-indepen-
dent activator 11S/PA28, PFI0370c, showing an identity of 33%
(P-value of 2.1e24), indicating that the plasmodial CP might also
be regulated independently from the RP. No homolog of PA200/
Blm10 was identiﬁed.
3. HslV: ancestral relict or essential enzyme?
In addition to homologs of the eukaryotic proteasome SUs, a
predicted bacteria-like proteasomal predecessor was identiﬁed
Fig. 1. The UPS of eukaryotes. The schematic depicts the structure of the 26S proteasome as well as protein ubiquitination, shuttle and deubiquitination, as experimentally
demonstrated in human and yeast. UPS proteins identiﬁed in P. falciparum are framed in black, proteins without homologs in P. falciparum are framed in grey. CP, core
particle; DUB, deubiquitinating enzyme; E, ubiquitinating enzyme; RA, regulatory activator; RP, regulatory particle; SU, subunit; Ub, ubiquitin.
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which was termed PfhslV (PFL1465c; Mordmüller et al., 2006).
Bacterial HslV exhibits moderate sequence similarities with
eukaryotic b-SUs (Rohrwild et al., 1996). The threonine peptidase
typically associates with the ATPase HslU, and the HslV/U complex
consists of two inner rings of six HslV-SUs per ring and two outer
rings of six HslU-SUs each. In E. coli, HslV is involved in the degra-
dation of regulatory or misfolded proteins, but it appears unessen-
tial for the bacterium (Missiakas et al., 1996; Kanemori et al., 1997;
Seong et al., 1999). In P. falciparum, an HslU homolog, PfhslU
(PFI0355c), was recently identiﬁed and in silico analyses predicted
an interaction between PfhslU and PfhslV (Subramaniam et al.,
2009).
The HslV threonine-peptidase has been identiﬁed in a variety of
protists (reviewed in Tschan et al., 2011), including localization
within the kinetoplast of Trypanosoma brucei, where it is involved
in replication of mitochondrial minicircles (Li et al., 2008). In P. fal-
ciparum, PfhslV was originally described to localize to the cyto-
plasm of blood stage parasites, where it is proteolytically active
and exhibiting threonine protease, chymotrypsin-like and peptidyl
glutamyl peptide hydrolase activities (Ramasamy et al., 2007). A
follow-up study assigned the nucleus-encoded PfhslV to the mito-
chondrion, to which it is transported by an N-terminal targeting
sequence (Tschan et al., 2010).While PfhslV is abundantly expressed in the asexual blood
stages, new data from our laboratory indicate that PfhslV expres-
sion decreases in gametocytes (Fig. 2C; Aminake and Pradel,
unpublished observations). Considering that in gametocytes the
mitochondrion becomes highly branched (Okamoto et al., 2009)
while the parasite shifts from glycolysis towards mitochondrial
respiration (van Dooren et al., 2006), the down-regulation of the
mitochondrion-assigned enzyme in these stages warrants future
study.
The attractiveness of PfhslV as a drug target is based on the ab-
sence of a homolog in the human host (Ramasamy et al., 2007).
However, it is not clear whether PfhslV is essential for the blood
stages or other life cycle stages of Plasmodium parasites. It might
be investigated if protease/proteasome inhibitors, discussed below
in Section 7, exert their effect on PfhslV instead of the 26S protea-
some. Reverse genetics approaches to disrupt the PfhslV gene locus
should shed light on these questions, and within the next years we
can expect to better understand the prokaryotic proteasome.4. Ubiquitin-tagging of proteins
Protein degradation is triggered by the carboxy-terminal tag-
ging of the 76 amino acid long protein Ub to surface-exposed lysine
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Fig. 2. (A) Subcellular localization of proteasome SUs and of PfhslV in the blood and gametocyte stages of P. falciparum. Indirect immunoﬂuorescence assays, using mouse
polyclonal antisera against a-SU type 5 (A) and b-SU type 5 (B) revealed localization of the two proteins in the asexual blood stages as well as in the gametocyte stages (stages
IIb and V depicted). Antibodies antisera against PfhslV (C) labeled the protein in the trophozoite and schizont stages, but not in gametocytes (green). Nuclei were highlighted
by Hoechst nuclear staining (blue); and erythrocytes were counterstained by Evans Blue (red). GC, gametocyte; RBC, red blood cell; RS; ring stage, SZ, schizont; TZ,
trophozoite. Bar, 5 lm. For detailed methods, see Supplementary data. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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them for degradation by the proteasome. Once the initial Ub is at-
tached, poly-ubiquitination of the substrate can occur through the
sequential transfer of additional Ubs. Substrates targeted for degra-
dation require an Ub chain of at least four residues. Proteins might
also be mono-ubiquitinated at single or multiple sites without
being targeted for degradation, and then function in cellular signal-
ing processes like DNA repair, endocytosis or trafﬁcking (reviewed
in Hicke, 2001; Hofmann, 2009; Clague and Urbe, 2010; Grabbe
et al., 2011).
Ub can be isolated as an 8.5 kDa protein from the cell either by
degradation of poly-Ub proteins or by proteolytic cleavage of Ub-
fusion proteins. In P. falciparum, a poly-ubiquitin encoding gene,
pfpUb, comprises ﬁve tandem repeats of the Ub open reading frame
(Table 2; Horrocks and Newbold, 2000). PfpUb is expressed in all
life cycle stages with a predominant expression in intraerythrocy-
tic parasites (Bozdech et al., 2003; Le Roch et al., 2003). Genesencoding two additional Ub-fusion proteins are present in P. falci-
parum, the uba52 homolog L40/UBI and S31/UBI (Table 2; Ponts
et al., 2008). The Ubs are fused to ribosomal proteins L40 and
S27a. The P. falciparum genome also encodes for an 8.5 kDa Nedd8
ortholog, an ubiquitin-like protein (ULP) which becomes covalently
conjugated to a limited number of cellular proteins in a manner
analogous to ubiquitination. Lastly, the genome encodes for a num-
ber of additional ULPs, including homologs to SUMO, Hub1, Urm1
and Atg8 (Table 2; Ponts et al., 2008). Proteins conjugated by ULPs
are generally not targeted for degradation by the proteasome, but
rather function in diverse regulatory activities.
Ub conjugation involves three groups of serially-connected en-
zymes, the Ub-activating enzyme E1, the Ub-conjugating enzyme
E2 and the Ub ligase E3 (Fig. 1). In an initial step, E1 binds Ub to
form an Ub-E1 thioester and transfers the residue to E2. Subse-
quently, E3 interacts with both E2 and the target protein, resulting
in the transfer of Ub from E2 to the substrate lysine residue. Unlike
Table 1
Homologs of human proteasome subunits a and b identiﬁed in P. falciparum.
Proteasome subunits Homo sapiens (accession number) P. falciparum (Plasmodb code) Identities (%) P-value
CP subunitso
Proteasome subunit a type 1 P25786 PF14_0716 44 8.7e52
Proteasome subunit a type 2 P25787 PFF0420c 57 3.2e70
Proteasome subunit a type 3 P25788 PFC0745c 34 3.7e44
Proteasome subunit a type 4 P25789 PF13_0282 53 3.4e66
Proteasome subunit a type 5 P28066 PF07_0112 54 5.5e66
Proteasome subunit a type 6 P60900 MAL8P1.128 45 3.1e56
Proteasome subunit a type 7 O14818 MAL13P1.270 53 2.6e59
Proteasome subunit b type 1 P20618 PFE0915c 43 4.0e47
Proteasome subunit b type 2 P49721 PF14_0676 37 6.3e33
Proteasome subunit b type 3 P49720 PFA0400c 43 3.7e44
Proteasome subunit b type 4 P28070 MAL8P1.142 42 6.0e41
Proteasome subunit b type 5 P28074 PF10_0111 53 1.2e59
Proteasome subunit b type 6 P28072 PFI1545c 29 8.3e27
Proteasome subunit b type 7 Q99436 PF13_0156 53 1.6e66
RP base subunits
26S protease regulatory subunit 7 or RPT1 P35998 PF13_0063 70 1.2e159
26S protease regulatory subunit 4 or RPT2 P62191 PF10_0081 77 1.5e168
26S protease regulatory subunit 6B or RPT3 P43686 PFD0665c 64 4.6e133
26S protease regulatory subunit 10B or RPT4 P62333 PF13_0033 67 2.8e142
26S protease regulatory subunit 6A or RPT5 P17980 PF11_0314 71 7.3e158
26S protease regulatory subunit 8 or RPT6 P62195 PFL2345c 74 2.0e155
26S proteasome non-ATPase regulatory subunit 2 or RPN1 Q13200 PFB0260w 37 1.5e143
26S proteasome non-ATPase regulatory subunit 1 or RPN2 Q99460 PF14_0632 43 1.3e161
26S proteasome non-ATPase regulatory subunit 4 or RPN10 P55036 PF08_0109 41 4.6e37
26S proteasome non-ATPase regulatory subunit RPN13 Q16186 PF14_0138 35 6.6e17
RP lid subunits
26S proteasome non-ATPase regulatory subunit 3 or RPN3 O43242 MAL13P1.190 35 3.4e73
26S proteasome non-ATPase regulatory subunit 12 or RPN5 O00232 PF10_0174 39 1.6e82
26S proteasome non-ATPase regulatory subunit 4 or RPN6 O00231 PF14_0025 35 5.3e51
26S proteasome non-ATPase regulatory subunit 6 or RPN 7 Q15008 PF11_0303 37 1.1e76
26S proteasome non-ATPase regulatory subunit 7 or RPN8 P51665 PFI0630w 39 9.3e55
26S proteasome non-ATPase regulatory subunit 13 or RPN9 Q9UNM6 PF10_0298 26 1.2e38
26S proteasome non-ATPase regulatory subunit 14 or RPN 11 O00487 MAL13P1.343 63 1.2e100
26S proteasome non-ATPase regulatory subunit 8 or RPN 12 P48556 PFC0520w 32 1.6e25
26S proteasome non-ATPase regulatory subunit RPN 15 or DSS1 P60896 MAL7P1.117 61 0.53
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E3 ligases provide substrate selectivity through a speciﬁc substrate
recognition domain or via other cofactors; and can accordingly be
divided into four major classes, the HECT, the RING, the PHD and
the U-box E3 enzymes (reviewed in Shi and Grossman, 2010).
In P. falciparum, eight putative E1-like enzymes, 14 putative E2-
like enzymes and 54 putative E3 ligases were identiﬁed (Table 2;
Ponts et al., 2008, reviewed in Chung and Le Roch, 2010). Only lim-
ited information is available on the functionality of these enzymes
in malaria parasites. A homolog for the Ub-conjugating enzyme 13
was identiﬁed in P. falciparum (PfUBC13, Table 2), and it was
shown that the PfUBC13 activity is regulated by the protein kinase
PfPK9 (Philip and Haystead, 2007). Le Roch and co-workers re-
cently reported ubiquitination activity and an essential function
of three of the parasite-speciﬁc E3 ligases (Chung and Le Roch,
2010). The authors pointed out that these enzymes might repre-
sent a prospective novel type of drug target due to their high diver-
gence and essentiality for the malaria parasite. In accordance with
this statement, recent studies on the human E3 ligase MDM2 and
the small molecule inhibitor MI-63 indicated that the targeted
inhibition of E3 enzymes can be achieved (Canner et al., 2009).
The transport of ubiquitinated substrate to the proteasome is
mediated by shuttle proteins (Fig. 1). Rpn10, described above as a
19SRPbaseprotein, is alsopresent in the cellwithoutanyproteasome
association and appears to function as a substrate shuttle. Other ex-
tra-proteasomal Ub-binding proteins functioning as shuttles are
Rad23, Dsk2 or Ddi1 (reviewed in Hartmann-Petersen and Gordon,
2004; Madura, 2004;Welchman et al., 2005). These proteins contain
anUb-like domainUbL,which canbind to theUb receptors of the pro-
teasome, aswell as theUb-bindingdomain,UbA (reviewed inBedfordet al., 2010). Orthologs of Rad23, Dsk2 and Ddi1 (Table 2) can be
identiﬁed in P. falciparum; namely, PF10_0114, PF11_0142 and
PF14_0090, exhibiting 29%, 27% and 34% identities, respectively
(P-values of 1.0e24, 5.2e34 and 3.5e32).
As the delivery of Ub-tagged proteins to the proteasome is
essential for proteolysis, drug targeting of the shuttle proteins
would in theory be an attractive approach to interfere with the
UPS. However, little is known on their suitability as drug targets.
One compound, termed girolline, is linked with blocking the deliv-
ery of Ub-tagged proteins to the proteasome (Tsukamoto et al.,
2004). However, its exact mode of action is not well known, and
in malaria parasites could also involve translation termination (Be-
noit-Vical et al., 2008).5. Protein deubiquitination
Prior to degradation by the proteasome, the Ubs are removed
from the substrate to make them available for subsequent
ubiquitination cycles. Ub removal is mediated by de-ubiquitinating
enzymes (DUBs; Fig. 1). DUBs are proteases involved in ULP matu-
ration, Ub removal and pUb chain editing (proof-reading; reviewed
in Bedford et al., 2011). While some DUBs disassemble Ub chains
non-speciﬁcally, the majority of them exhibit substrate-speciﬁcity.
In humans, DUBs are classiﬁed into ﬁve conserved families, JAMM,
UCH, USP, OTU and MJD. All DUBs are cysteine proteases, with the
exception of the JAMM zinc metalloproteases (reviewed in Shi and
Grossman, 2010).
The 19S RP lid component Rpn11 exhibits de-ubiquitinating
activity. Other DUBs are not part of the proteasome, but interact
Table 2
UPS components identiﬁed in P. falciparum.
UPS component Plasmodb code UPS component Plasmodb code
Ub and ULPsa E3 Ub-ligasesa
polyUb PFL0585w HECT MAL8P1.23
L40/UBI PF13_0346 HECT PF11_0201
S31/UBI PF14_0027 HECT MAL7P1.19
Nedd8 MAL13P1.64 HECT PFF1365c
SUMO PFE0285c Cullin PF08_0094
Hub1 PFL1830w Cullin PFF1445c
Atg8 PF10_0193 F-box PFF0960c
Urm1 PF11_0393 F-box PFF0710w
E1 Ub-activating enzymesa F-box PFL1565c
UBA1 PFL1245w U-box PF08_0020
UBA2 PFL1790w U-box PFC0365w
UBA3 MAL8P1.75 U-box PF07_0026
UBA4 PF13_0344 RING ﬁnger PFL2440w
UBA1-like PF13_0182 RING ﬁnger PF11_0330
Atg7 PF11_0271 RING ﬁnger PFI0470w
Other PF13_0264 RING ﬁnger MAL13P1.405
Other PF11_0457 RING ﬁnger PFE1490c
E2 Ub-conjugating enzymesa RING ﬁnger PF14_0215
UBC9 PFI0740c RING ﬁnger PFF1325c
UBC12 PFL2175w RING ﬁnger PFC0610c
UBC13 PFE1350c RING ﬁnger PFL0275w
UEV PFC0255c RING ﬁnger PFF0165c
Other PFL0190w RING ﬁnger PF10_0117
Other PF13_0301 RING ﬁnger PF11_0244
Other PFF0305c RING ﬁnger PFF0355c
Other PF10_0330 RING ﬁnger PF10_0046
Other PF08_0085 RING ﬁnger PF14_0054
Other PFC0855w RING ﬁnger PFC0740c
Other PFI1030c RING ﬁnger PF10_0276
Other PFL2100w RING ﬁnger PFD0765w
Other PF14_0128 RING ﬁnger PF10_0072
Other MAL13P1.227 RING ﬁnger PFE0610c
DUBsa RING ﬁnger PFB0440c
UCH PF13_0096 RING ﬁnger PFC0510w
UCH PFE0835w RING ﬁnger MAL13P1.216
UCH MAL7P1.147 RING ﬁnger PFL0440c
UCH PFD0655c RING ﬁnger PF13_0188
UCH PFA0220w RING ﬁnger PFE0100w
UCH PF14_0145 RING ﬁnger PF14_0416
UCH PFD0165w RING ﬁnger PFF1180w
UCH PFI0225w RING ﬁnger PFF0755c
PfUCHL3 PF14_0576 RING ﬁnger MAL13P1.302
PfUCH54 PF11_0177 RING ﬁnger MAL13P1.345
USP14 PFE1355c RING ﬁnger MAL7P1.155
Josephin PFL1295w RING ﬁnger PFC0690c
Josephin PF11_0125 RING ﬁnger PFL1705w
Mov34 MAL13P1.343 RING ﬁnger PFC0845c
Mov34 PFI0630w RING ﬁnger PFI0805w
Mov34 PFI0895c RING ﬁnger PFL1620w
Mov34 PFD0265w RING ﬁnger PFC0175w
Mov34 PF10_0233 RING ﬁnger PF14_0139
Mov34 PF11_0409 RING ﬁnger PFC0425w
DUF862 PFL0865w RING ﬁnger MAL13P1.224
DUF862 PF10_0069 RING ﬁnger MAL13P1.122
DUF862 PFI0940c Shuttle proteins
OTU PF10_0308 Rad23 PF10_0114
OTU PFI1135c Dsk2 PF11_0142
OTU PF11_0428 Ddi1 PF14_0090
WLM PF10_0092
Peptidase_C48 PFL1635w
Peptidase_C48 MAL8P1.157
Peptidase_C54 PF14_0171
a Modiﬁed from Ponts et al. (2008).
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in Xie, 2010); among them Ubp6/USP14 and Uch2/Uch37 of yeast
and human. Uch2/Uch37 interacts with the proteasomal Ub recep-
tor Rpn13, and both Ubp6/USP14 and Uch2/Uch37 may serve as
‘‘proof-reading’’ enzymes to remove Ub chains from proteins that
are mistakenly encountered and ubiquitinated by the UPS (re-
viewed in Kraut et al., 2007).In P. falciparum, two independent studies identiﬁed 18 and 29
DUBs, respectively (Table 2; Ponder and Bogyo, 2007; Ponts
et al., 2008). Homologs of human UCH37, PfUCH54; and of UCHL3,
PfUCHL3 (Table 2), were identiﬁed in P. falciparum and known to
exhibit deubiquitinating and deNeddylating activities (Artavanis-
Tsakonas et al., 2006, 2010; Frickel et al., 2007). A putative homo-
log of human USP14 (PFE1355c) is also present in P. falciparum
(33% identities, P-value = 6.9e43).
Due to their intrinsic protease activity, plasmodial DUBs might
represent excellent targets for antimalarial drug discovery. Parasite
cysteine proteases have been of interest due to their involvement
in hemoglobin degradation (reviewed in Rosenthal, 2011). Com-
prehensive studies in malaria parasites would be feasible to deter-
mine the effect on Ub-protein accumulation of antiplasmodial
cysteine protease inhibitors and currently available DUB inhibitors
(such as Ubal, UbVS or cyclopentenon; reviewed in Daviet and Col-
land, 2008). The deNeddylating activities of PfUCH54 and PfUCHL3
might be of particular interest for drug design, since such activity is
not known for the mammalian homologs of the two DUBs.6. Inhibitors of the 20S proteasome
Several distinct kinds of proteasome inhibitors can be discerned
(reviewed in Verdoes et al., 2009). First, chemically reactive b-lac-
tone natural products such as lactacystin or salinosporamide A
have been found (Fig. 3). These mechanism-based ‘‘suicide’’ inhib-
itors undergo covalent attachment to the threonine in the active
centers of the b-SUs by nucleophilic opening of the b-lactone ring.
For lactacystin, the b-lactone containing intermediate ormulide is
formed slowly in situ from its cystein thioester. These compounds
are of high appeal in basic science, but their reactive promiscuity
and high toxicity render potential applications remote.
Secondly, a large variety of substrate mimetics has been re-
ported which emulate the endogenous peptides processed by the
proteasome and thereby achieve higher selectivity amongst other
cellular proteases. Both natural products (epoxomicin, fellutamide
B) and designed compounds (MG-132, bortezomib) have been
developed and intensively characterized (Fig. 3), in some cases
leading to success in the clinic (bortezomib). Most of these sub-
strate-competitive molecules carry a chemically reactive ‘‘war-
head’’ at the C-terminus to deactivate the proteasome (e.g.
epoxyketone, aldehyde, boronic acid) intermittently or even irre-
versibly. However, recently reversible high-afﬁnity inhibitors of
this kind have been reported as well (Blackburn et al., 2010), which
do not undergo a covalent attachment. Furthermore, by appropri-
ate tailoring of the chemical structures, subsite-speciﬁcity for the
CP-SUs b1, b2, or b5 was achieved (Britton et al., 2009).
Thirdly, several complex natural products of the cyclic peptide
(argyrins) or peptide alkaloid type (TMC compounds, thiostrepton)
inhibit proteasome function (Fig. 3). Apparently, none of these
inhibitors undergoes covalent attachment to the proteasome, but
rather high activity was found for these compounds or their deriv-
atives. In the case of the argyrins, efﬁcacy in cancer-focused animal
models was demonstrated (Nickeleit et al., 2008). While the bind-
ing site for TMC-95A was structurally characterized and found to
be located at the active centers of the b-SUs (Groll et al., 2006),
the site of action is much less clear for argyrin and thiostrepton.
Both compounds are quite large and might not easily pass the en-
try rim formed by the a-SUs. Hence, although potential binding of
argyrin at the active centers was recently suggested by molecular
modeling (Stauch et al., 2010), other less direct or allosteric modes
of action could also be involved, especially for thiostrepton
derivatives.
Overall, the intense search for drug candidates in the anti-can-
cer area has generated a constant stream of non-covalent and cova-
Fig. 3. Chemical structures of proteasome inhibitors. Functional groups undergoing covalent attachment to the proteasome active centers are highlighted in red. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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improving structural data. While it remains to be clariﬁed to which
degree functional or molecular inter-species selectivity between
humans and Plasmodium parasites can be achieved, this broad ba-
sis of bioactive lead compounds with broadly tested toxicity pro-
ﬁles will be highly useful in the future to inspire new compound
designs and support screening campaigns in Plasmodium infection
models.
7. The plasmodial proteasome: a multi-stage drug target?
Due to the essential roles of the UPS in all eukaryotic cells, one
might expect that proteasome inhibitors show activities against
malaria parasites as well. While it was shown in yeast and humanTable 3
The antimalarial effect of selected proteasome inhibitors.
Liver stages (100% inhibition) [lM] Blood stages (IC50) [lM]
Bortezomib n.d. 0.03–0.56c,d
Epoxomicin n.d. 0.002–0.03d,g
Lactacystin 9.0a 1.2–1.5a
MG-132 n.d. 0.04–0.05e,g
MLN273 1.0b 0.04b
Salinosporamide A n.d. 0.01e
Thiostrepton n.d. 8.9–16.7g
n.d., not determined.
a Gantt et al. (1998).
b Lindenthal et al. (2005).
c Reynolds et al. (2007).
d Kreidenweiss et al. (2008).
e Prudhomme et al. (2008).
f Czesny et al. (2009).
g Aminake et al. (2011).that the CP-SUs b1, b2 and b5 display caspase-like, trypsin-like and
chymotrypsin-like activities, respectively, such distinct activities
have not been conﬁrmed for Plasmodium, and interaction of active
site-targeting inhibitors with CP-SUs have yet to be demonstrated.
However, epoxomicin was reported to bind parasite CP-SUs b2 and
b5 (Mordmüller et al., 2006) and bortezomib, which exhibits anti-
plasmodial activities, has a high speciﬁcity for b5 (Oerlemans et al.,
2008), providing indirect evidence for the proteolytically active
sites of the plasmodial proteasome.
Among active-site targeting proteasome inhibitors, lactacystin,
salinosporamide A, MG 132, epoxomicin, and bortezomib were
tested for efﬁcacy against P. falciparum and reported to inhibit par-
asite growth in vitro at low nanomolar concentrations (Table 3;
Gantt et al., 1998; Reynolds et al., 2007; Kreidenweiss et al.,Gametocytes (100% elimination) [lM] Transmission (100% reduction) [lM]
n.d. n.d.
0.03f,g 0.1f
n.d. n.d.
0.5g n.d.
n.d. n.d.
n.d. n.d.
8.9g n.d.
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inhibitors are fast acting, and drug-treated parasites were reported
to be arrested prior to DNA replication (Reynolds et al., 2007; Kre-
idenweiss et al., 2008; Aminake et al., 2011), thus at a time point
when protein ubiquitination is at a peak (Ponts et al., 2011). Ubiq-
uitinated protein accumulation was observed in the parasite lysate
after treatment of the parasite with proteasome inhibitors, provid-
ing indirect evidence that the proteasome is affected (Lindenthal
et al., 2005; Aminake et al., 2011).
In addition to their effect on blood stage parasites, the protea-
some inhibitors lactacystin and MLN273 (a compound related to
bortezomib) were reported to have an effect on the liver stages
in vitro, when applied in the micromolar range (Table 3; Gantt
et al., 1998; Lindenthal et al., 2005). Both inhibitors blocked the
development of exoerythrocytic forms in liver hepatoma cells
in vitro, and lactacystin was further shown to inhibit infectivity
in the P. bergheimouse model in vivo (Gantt et al., 1998). The effect
of other proteasome inhibitors on the liver stages of Plasmodium
has not been tested. Few antimalarials known to target liver stage
are available; for example, the 8-aminoquinolines primaquine and
tafenoquine. The fact that proteasome inhibitors exhibit activities
against the liver and blood stages, makes them particularly inter-
esting for malaria therapy. MG-132 and epoxomicin were recently
reported to exhibit gametocytocidal activities in vitro in their IC50-
90 concentrations, thereby eliminating the gametocytes from the
cultures within two days of drug incubation, and in consequence
reducing parasite transmission from the human to the mosquito
(Table 3; Czesny et al., 2009; Aminake et al., 2011). Gametocytocid-
al activities have been demonstrated for few antimalarials, includ-
ing primaquine and artemisinin (Pukrittayakamee et al., 2004). The
development of novel antimalarials with gametocytocidal activi-
ties is therefore urgently needed and is currently promoted by
the WHO and the Bill and Melinda Gates Foundation.
Gametocytes are the sexual precursor cells of the malaria para-
site, which form in the human blood in response to stress, and
likely other unknown cues (reviewed in Talman et al., 2004).
Gametocytes develop from stage I to stage V during a period of
approximately 10 days, before continuing their life cycle in the
mosquito vector (reviewed in Pradel, 2007; Kuehn and Pradel,
2010). When investigating the gametocytocidal effect of epoxomi-
cin in detail, we recently observed that the inhibitor exerted its ef-
fect on gametocytes during maturation from the early to the
mature stages (Aminake et al., unpublished observations). The
maturation of gametocytes is accompanied by high protein turn-
over rates, which is particularly reﬂected by the sequential expres-
sion of a high number of surface-associated proteins, like Pfs16,
Pfs230, Pfs48/45 and the LCCL-domain proteins (reviewed in Pra-
del, 2007; Kuehn and Pradel, 2010), and these changes in the com-
position of surface proteins might be regulated by the plasmodial
UPS.
Thiostrepton was recently identiﬁed as an inhibitor of the pro-
teasome, although the compound was described in the 1950s as a
strong antibiotic with high activity against Gram-positive strains
(reviewed in Bagley et al., 2005) and is used as a topical antibiotic
in veterinary medicine. Its activity is mediated by tight binding to
the GTPase-associated region of the bacterial 70S ribosome, which
then stalls during protein translocation (Harms et al., 2008; Jonker
et al., 2011). Due to genetic and functional similarity of the ribo-
somes in bacteria and eukaryotic organelles, thiostrepton impairs
protein biosynthesis in the mitochondrion and in the apicoplast
of malaria parasites (McConkey et al., 1997; Tarr et al., 2011). How-
ever, the rapid killing induced by thiostrepton and its derivatives is
contrary to the delayed death effect of other apicoplast-targeting
antibiotics (reviewed in Pradel and Schlitzer, 2010), and this might
be explained by invoking an additional target. The target was re-
cently identiﬁed as the proteasome by cell microscopy, enzymaticactivity studies and phenotype proﬁling (Schoof et al., 2010; Ami-
nake et al., 2011). While thiostrepton exhibits only moderate anti-
plasmodial activities in vitro, derivatives are active in the low
micromolar range (Table 2; Schoof et al., 2010; Aminake et al.,
2011). Taken together, thiostrepton derivatives combine in one
molecular structure two modes of action against P. falciparum,
and this unique duality might reduce the likelihood of resistance.
8. Future perspectives
The plasmodial proteasome can be viewed as a candidate multi-
stage drug target, and progression of our understanding might ben-
eﬁt from the experience and reagents gained during the develop-
ment of anti-cancer proteasome inhibitors. It will nonetheless
remain challenging to identify inhibitors which are sufﬁciently
speciﬁc to the microorganism; that is, with a high therapeutic in-
dex allowing treatment of human malaria. In the case of aggres-
sively dividing myeloma a sufﬁcient therapeutic window was
found for bortezomib, which suggests that proteasome inhibitors
could become an effective treatment or at least component for
an acute therapy against the rapidly developing blood stages of
Plasmodium. To reach a sufﬁcient therapeutic index and to tar-
get also the more hidden and diluted liver and gametocyte stages,
species-selective agents would be highly desirable. Along this line,
encouraging data was recently reported for Mycobacterium tuber-
culosis, for which a species-selective proteasome inhibitor was
found (Lin et al., 2009). Therefore, further characterization of the
biochemistry and cell biology of the UPS in Plasmodium will not
only help unravel its unique biology in a multi-stage parasitic
organism, but also potentially enable the discovery of new antima-
larial drugs.
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